Novavax has become the next company to have an updated version of its Covid-19 vaccine approved in the US. The Food and Drug Administration (FDA) amended the emergency use authorisation (EUA) of the Novavax Covid-19 Vaccine, Adjuvanted, for use in individuals 12 years of age and… Read More
The R21/Matrix-M malaria vaccine has been recommended for use by the World Health Organization’s Strategic Advisory Group of Experts (SAGE) and the Malaria Policy Advisory Group (MPAG). Developed by The University of Oxford and the Serum Institute of India, leveraging Novavax’s adjuvant technology, R21/Matrix-M malaria vaccine… Read More
It is believed that new Covid-19 vaccines developed by Pfizer/BioNTech, Moderna and Novavax will be effective against the fast-spreading EG.5 strain. EG.5 or ‘Eris’ has been found in more than 50 countries. It is the most common and fastest growing Covid-19 subvariant in the US, estimated… Read More
Pharmaceutical company Novavax is attempting to expand the use of its Covid-19 vaccine Nuvaxovid into adolescents aged 12-17 year and as a booster dose for adults. The company has submitted a request to Swissmedic to expand the conditional marketing authorisation (CMA) of Nuvaxovid. The request is based… Read More
The recent approval of Novavax’s protein-based Covid-19 vaccine for adolescents aged 12-18 years will help its partner, the Serum Institute of India (SII) enter the adolescents’ market, according to GlobalData. Novavax’s Covid-19 vaccine was granted emergency use authorisation by the Drugs Controller General of India (DCGI) in… Read More
